Literature DB >> 31615932

Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem.

Cecilia Larocca1, Thomas S Kupper2, Nicole R LeBoeuf1.   

Abstract

Mogamulizumab, approved by the FDA for relapsed or refractory mycosis fungoides and Sézary syndrome, improves progression-free survival compared with vorinostat in the largest trial to date in cutaneous T-cell lymphoma, with particular efficacy in leukemic disease, but carries a risk of immune-mediated toxicities with concomitant depletion of regulatory T cells.See related article by Kasamon et al., p. 7275. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31615932      PMCID： PMC7147994          DOI： 10.1158/1078-0432.CCR-19-2742

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.

Authors:  Rachael A Clark; Rei Watanabe; Jessica E Teague; Christoph Schlapbach; Marianne C Tawa; Natalie Adams; Andrew A Dorosario; Keri S Chaney; Corey S Cutler; Nicole R Leboeuf; Joi B Carter; David C Fisher; Thomas S Kupper
Journal:  Sci Transl Med       Date:  2012-01-18       Impact factor: 17.956

2.  Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors.

Authors:  James J Campbell; Rachael A Clark; Rei Watanabe; Thomas S Kupper
Journal:  Blood       Date:  2010-05-18       Impact factor: 22.113

3.  The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors.

Authors:  Kazuki Hirahara; Luzheng Liu; Rachael A Clark; Kei-ichi Yamanaka; Robert C Fuhlbrigge; Thomas S Kupper
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

4.  FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.

Authors:  Yvette L Kasamon; Haiyan Chen; R Angelo de Claro; Lei Nie; Jingjing Ye; Gideon M Blumenthal; Ann T Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2019-07-31       Impact factor: 12.531

5.  Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission.

Authors:  Rei Watanabe; Jessica E Teague; David C Fisher; Thomas S Kupper; Rachael A Clark
Journal:  JAMA Dermatol       Date:  2014-07       Impact factor: 10.282

6.  Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.

Authors:  P Bonnet; M Battistella; M Roelens; C Ram-Wolff; F Herms; L Frumholtz; J-D Bouaziz; P Brice; H Moins-Teisserenc; M Bagot; A de Masson
Journal:  Br J Dermatol       Date:  2018-11-22       Impact factor: 9.302

7.  Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.

Authors:  Xiao Ni; Jeffrey L Jorgensen; Meghali Goswami; Pramoda Challagundla; William K Decker; Youn H Kim; Madeleine A Duvic
Journal:  Clin Cancer Res       Date:  2014-11-05       Impact factor: 12.531

8.  FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.

Authors:  L M Gjerdrum; A Woetmann; N Odum; C M Burton; K Rossen; G L Skovgaard; L P Ryder; E Ralfkiaer
Journal:  Leukemia       Date:  2007-08-23       Impact factor: 11.528

9.  Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.

Authors:  Shigeo Fuji; Yoshitaka Inoue; Atae Utsunomiya; Yukiyoshi Moriuchi; Kaoru Uchimaru; Ilseung Choi; Eiichi Otsuka; Hideho Henzan; Koji Kato; Takeaki Tomoyose; Hisashi Yamamoto; Saiko Kurosawa; Ken-Ichi Matsuoka; Takuhiro Yamaguchi; Takahiro Fukuda
Journal:  J Clin Oncol       Date:  2016-08-09       Impact factor: 44.544

10.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Authors:  Youn H Kim; Martine Bagot; Lauren Pinter-Brown; Alain H Rook; Pierluigi Porcu; Steven M Horwitz; Sean Whittaker; Yoshiki Tokura; Maarten Vermeer; Pier Luigi Zinzani; Lubomir Sokol; Stephen Morris; Ellen J Kim; Pablo L Ortiz-Romero; Herbert Eradat; Julia Scarisbrick; Athanasios Tsianakas; Craig Elmets; Stephane Dalle; David C Fisher; Ahmad Halwani; Brian Poligone; John Greer; Maria Teresa Fierro; Amit Khot; Alison J Moskowitz; Amy Musiek; Andrei Shustov; Barbara Pro; Larisa J Geskin; Karen Dwyer; Junji Moriya; Mollie Leoni; Jeffrey S Humphrey; Stacie Hudgens; Dmitri O Grebennik; Kensei Tobinai; Madeleine Duvic
Journal:  Lancet Oncol       Date:  2018-08-09       Impact factor: 41.316
View more
  1 in total

1.  Alopecia areata after mogamulizumab treatment.

Authors:  Neel S Raval; Nora A Alexander; Karlee De Monnin; Christine C Yokoyama; Neha Mehta-Shah; Ilana S Rosman; Amy C Musiek
Journal:  JAAD Case Rep       Date:  2021-11-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.